@article {Lu2021.03.19.21253974, author = {Dan Lu and Alberto Aleta and Marco Ajelli and Romualdo Pastor-Satorras and Alessandro Vespignani and Yamir Moreno}, title = {Data-driven estimate of SARS-CoV-2 herd immunity threshold in populations with individual contact pattern variations}, elocation-id = {2021.03.19.21253974}, year = {2021}, doi = {10.1101/2021.03.19.21253974}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The development of efficacious vaccines has made it possible to envision mass vaccination programs aimed at suppressing SARS-CoV-2 transmission around the world. Here we use a data-driven age-structured multilayer representation of the population of 34 countries to estimate the disease induced immunity threshold, accounting for the contact variability across individuals. We show that the herd immunization threshold of random (un-prioritized) mass vaccination programs is generally larger than the disease induced immunity threshold. We use the model to test two additional vaccine prioritization strategies, transmission-focused and age-based, in which individuals are inoculated either according to their behavior (number of contacts) or infection fatality risk, respectively. Our results show that in the case of a sterilizing vaccine the behavioral strategy achieves herd-immunity at a coverage comparable to the disease-induced immunity threshold, but it appears to have inferior performance in averting deaths than the risk vaccination strategy. The presented results have potential use in defining the effects that the heterogeneity of social mixing and contact patterns has on herd immunity levels and the deployment of vaccine prioritization strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementY.M. acknowledges partial support from the Government of Aragon and FEDER funds, Spain through grant E36-20R (FENOL), and by MINECO and FEDER funds (FIS2017-87519-P). A.A. and Y.M. acknowledge support from Banco Santander (Santander-UZ 2020/0274) and Intesa Sanpaolo Innovation Center. M.A. and A.V acknowledge the support of the Cooperative Agreement number NU38OT000297 from The Centers for Disease Control and Prevention (CDC) and CSTE. RPS acknowledge financial support from the Spanish MICINN, under Project No. PID2019-106290GB-C21. D.L. acknowledges support from the China Scholarship Council though a PhD fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:n/aAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used is publicly available.}, URL = {https://www.medrxiv.org/content/early/2021/03/20/2021.03.19.21253974}, eprint = {https://www.medrxiv.org/content/early/2021/03/20/2021.03.19.21253974.full.pdf}, journal = {medRxiv} }